Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Puma Biotech. target lowered to $17 at RBC Capital Mkts; APHINITY hits; extended adjuvant is done; 3rd-line metastatic Phase III data 1H17 (38.05)RBC Capital Mkts lowers their PBYI tgt to $17 from $48. Following positive APHINITY, the focus shifts to the metastatic setting and the ongoing Phase III trial in 3rd-line vs. lapatinib (1H17). Neratinib is certainly an active agent, so it has a decent chance against lapatinib; the GI AE profile and the difficulty finding a prophylactic treatment that works limit its commercial potential; however, this will be less of an issue in the metastatic setting.</td> </tr></table>"